| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/22/2001 | WO2000077246A3 A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS |
| 02/22/2001 | WO2000077179A3 Human poly(adp-ribose) polymerase 2 materials and methods |
| 02/22/2001 | WO2000071538A3 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/22/2001 | WO2000071514A8 α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS |
| 02/22/2001 | WO2000064936A3 PEPTIDE HOMODIMERS AND PEPTIDE HETERODIMERS, DERIVED FROM INTERFERON α2 |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO2000050418A9 Heterocyclic benzenesulphonamide compounds as bradykinine antagonists |
| 02/22/2001 | WO1999049883A3 Oxidized thymosin beta 4 |
| 02/22/2001 | DE19940220A1 Preparation for treating rheumatic joint diseases, e.g. arthritis, comprising injectable, induction heatable, iron oxide-based magnetic particles including radionuclide and cytotoxic agent |
| 02/22/2001 | DE19939463A1 Tryptase inhibitors useful e.g. for treating inflammatory or allergic disease, arteriosclerosis or neoplasia, comprising new or known 2-phenethyl-benzimidazole-5-carboxamides |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2452118A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2385487A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | CA2383922A1 Cytokine receptor common gamma chain like |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2383154A1 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2382018A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2382015A1 Membrane associated proteins |
| 02/22/2001 | CA2381975A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| 02/22/2001 | CA2381971A1 Amines substituted with a tetrahydroquinolinyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological acitity |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2380966A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380432A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | CA2379356A1 Novel hypoxanthine and thiohypoxanthine compounds |
| 02/22/2001 | CA2378332A1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/21/2001 | EP1076645A1 Process for the preparation of methyl(2s)-2-[(3r)-3-(n-[tert-butyloxycarbonyl]-amino) -2-oxopyrr olidin-1-yl]propionate |
| 02/21/2001 | EP1076641A1 Inhibitors of impdh enzyme |
| 02/21/2001 | EP1076553A2 Pharmaceutical, hygienic and/or cosmetic compositions containing sea water and uses |
| 02/21/2001 | EP0871470A4 Haemopoietic growth factor antagonists and uses therefor |
| 02/21/2001 | EP0784683B1 Tie-2 ligands, methods of making and uses thereof |
| 02/21/2001 | CN1284994A Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
| 02/21/2001 | CN1284957A Imidazonaphthyridines and their use in inducing cytokine biosynthesis |
| 02/21/2001 | CN1284947A Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/21/2001 | CN1284945A Substituted pyriding and pyridazine compounds and their pharmaceutical use |
| 02/21/2001 | CN1284944A Integrin receptor antagonists |
| 02/21/2001 | CN1284943A Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods therewith |
| 02/21/2001 | CN1284942A Matrix metalloprotease inhibitors |
| 02/21/2001 | CN1284863A Topical compositions for NSAI drug delivery |
| 02/21/2001 | CN1284370A Chinese medicine for treating rheumatoid disease |
| 02/21/2001 | CN1284362A Tonic wine for treating kidney wetness |
| 02/21/2001 | CN1284352A Application of breviscapine seoul wildginger herb oral preparation in pharmacy |
| 02/21/2001 | CN1062182C Novel physiologically active substance |
| 02/21/2001 | CN1062173C Traditional chinese medicine preparation for curing rheumatism and its preparing method |
| 02/21/2001 | CN1062129C Medicine matrix and its use |
| 02/20/2001 | US6191304 Vitronectin receptor antagonists |
| 02/20/2001 | US6191271 Synthetic divalent sLex containing polylactosamines and methods for use |
| 02/20/2001 | US6191266 Sugar modified nucleosides |
| 02/20/2001 | US6191172 Used in drugs and cosmetics |
| 02/20/2001 | US6191135 Respiratory system disorders, antiinflammatory agents; analgesics |
| 02/20/2001 | US6191127 Antiinflammatory agents, autoimmune diseases, cardiovascular disorders, nervous system disorders |
| 02/20/2001 | US6191121 Treatment of skin damage using polyenylphosphatidylcholine |
| 02/20/2001 | US6191104 Methods of treating graft rejection with the IL-17 receptor |
| 02/20/2001 | US6190875 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 02/20/2001 | CA2223624C Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines |
| 02/20/2001 | CA2192289C Substituted heterocyclic derivatives |
| 02/20/2001 | CA2191789C Biaromatic compounds containing an adamantyl group in ortho position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 02/20/2001 | CA2122519C Cancer treatment and metastasis prevention |
| 02/15/2001 | WO2001011050A1 Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY |
| 02/15/2001 | WO2001011027A1 New protein |
| 02/15/2001 | WO2001011023A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | WO2001010893A2 Il-16 antagonists |
| 02/15/2001 | WO2001010865A1 p38MAP KINASE INHIBITORS |
| 02/15/2001 | WO2001010859A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | WO2001010847A2 Novel integrin receptor antagonists |
| 02/15/2001 | WO2001010833A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | WO2001010831A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 02/15/2001 | WO2001010829A1 Novel vitamin d analogues |
| 02/15/2001 | WO2001010827A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 02/15/2001 | WO2001010816A2 Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 02/15/2001 | WO2001010741A1 Valve with a two-component seal |
| 02/15/2001 | WO2001010457A2 Pharmaceutical compositions containing tripeptides |
| 02/15/2001 | WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | WO2001010439A1 Cyclic amine ccr3 antagonists |
| 02/15/2001 | WO2001010423A2 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010411A2 Implantable active ingredient depot |
| 02/15/2001 | WO2001010409A1 Aqueous nasal formulation |
| 02/15/2001 | WO2001010385A2 1,4-substituted 4,4-diaryl cyclohexanes |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010381A2 Methods for treating or preventing pain and anxiety |
| 02/15/2001 | WO2001010323A1 Method of controlling body temperature while reducing shivering |
| 02/15/2001 | WO2001010221A1 Vaccines for the treatment of autoimmune disease |
| 02/15/2001 | WO2000069884A3 Compositions isolated from skin cells and methods for their use |
| 02/15/2001 | WO2000069843A3 Cycloalkyl substituted 3-urea-benzofurane-and -pyridofurane-derivatives |
| 02/15/2001 | WO2000066067A3 Ibd-associated microbial antigens and methods of using same |
| 02/15/2001 | WO2000064874A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/15/2001 | WO2000062740A3 Skin care compositions containing combination of skin care actives |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000049144A3 Pyk2 binding proteins |
| 02/15/2001 | WO2000043419A3 Exocytosis pathway proteins and methods of use |
| 02/15/2001 | DE19937656A1 Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen The use of antithrombin III for the prophylaxis and treatment of diseases |
| 02/15/2001 | DE19936780A1 Neue Antagonisten von Integrinrezeptoren New antagonists of integrin |